PlumX Metrics
Embed PlumX Metrics

Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats

Arzneimittel-Forschung/Drug Research, ISSN: 0004-4172, Vol: 58, Issue: 11, Page: 574-580
2008
  • 25
    Citations
  • 0
    Usage
  • 14
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

AVE2268, a substituted glycopyranoside, is an orally active and selective inhibitor of sodium-dependent glucose transporter 2 (SGLT2; IC=13 nmol/L). Investigation of the pharmacological profile of AVE2268 on urinary glucose excretion (UGE) and blood glucose after glucose challenge (po or intraperitoneal) was performed in mice and rats. AVE2268 caused a dose-dependent increase of UGE in mice (ID = 79 ± 8.1 mg/kg p.o.) and rats (ID = 39.8 ± 4.0 mg/kg p.o.). AVE2268 in mice was more potent to decrease blood glucose ascent when glucose was given intraperitoneally (ID = 13.2 ± 3.9 mg/kg), compared to orally administered glucose (ID = 26.1 ± 3.9 mg/kg), showing that AVE2268 has no effects on SGLT 1 in the gut in vivo, which is in accordance with ist very low affinity to the SGLT 1 in vitro (IC > 10,000 nmol/L). During an oral glucose tolerance test, AVE2268 dose-dependently increased UGE, with subsequent decreases of AUC and blood glucose. A highly significant inverse correlation between AUC and UGE was found (p<0.001).The increase in UGE is linked to the inhibition of SGLT2 only. This profile renders AVE2268 as a new antidiabetic drug for the treatment of type 2 diabetes. © ECV Editio Cantor Verlag.

Bibliographic Details

Bickel, Martin; Brummerhop, Harm; Frick, Wendelin; Glombik, Heiner; Herling, Andreas Waldemar; Heuer, Hubert Otto; Plettenburg, Oliver; Theis, Stefan; Werner, Ulrich; Kramer, Werner

Georg Thieme Verlag KG

Pharmacology, Toxicology and Pharmaceutics

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know